More about Cu-67 PSMA : it seems better than Pluvicto (Lutetium) and it looks like experts are pushing it toward first line treatment!

[Maxone73]

I have already talked about this but it continues to look promising, so here is an update:

urotoday.com/video-lectures...

in a nutshell, improved Pluvicto:

"the SECuRE trial for PSMA-targeted radiopharmaceutical in prostate cancer showcases a unique design with double PSMA binding sites and a proprietary SAR chelator, enhancing drug delivery and reducing systemic leakage. Utilizing copper 64 for precise imaging and copper 67 for targeted therapy, the trial has shown promising preclinical and early clinical results with significant tumor targeting and low toxicity. Benefits include fewer required doses, improved patient convenience, and scalable production. The trial's success could lead to broader accessibility and potential FDA approval, offering an effective alternative to current therapies with better safety and patient outcomes."

[TC007]

improved Pluvicto is urgently required. I am following this as well very eagerly and this really looks promising. Hopefully, this will be taken up by FDA on priority specially looking at the limited options available

[j-o-h-n]

The one thing I admire about you, is that you're an optimist (to the Max).... so -

Good Luck, Good Health and Good Humor.

j-o-h-n